Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoMed Therapeutics's Other Operating Expense for the
six
months ended in Dec. 2025 was €0.29 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €0.29 Mil.
CytoMed Therapeutics's quarterly Other Operating Expense
increased
from Dec. 2024 (€-0.02 Mil) to Jun. 2025 (€-0.00 Mil) and
increased
from Jun. 2025 (€-0.00 Mil) to Dec. 2025 (€0.29 Mil).
CytoMed Therapeutics's annual Other Operating Expense
declined
from Dec. 2023 (€0.67 Mil) to Dec. 2024 (€0.00 Mil) but then
increased
from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.29 Mil).
CytoMed Therapeutics Other Operating Expense Related Terms
CytoMed Therapeutics Other Operating Expense Historical Data
* Premium members only.
The historical data trend for CytoMed Therapeutics's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoMed Therapeutics Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €0.29 Mil mean?
CytoMed Therapeutics (FRA:F98) has a Other Operating Expense of €0.29 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on CytoMed Therapeutics and its competitors.
Is CytoMed Therapeutics' Other Operating Expense too high?
CytoMed Therapeutics' current Other Operating Expense is €0.29 Mil. Overall, CytoMed Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' Other Operating Expense compare to LEXX and INAB?
CytoMed Therapeutics' Other Operating Expense of €0.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on CytoMed Therapeutics and its competitors. CytoMed Therapeutics's current Other Operating Expense is €0.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (FRA:F98) has a current Other Operating Expense of €0.29 Mil. The current Other Operating Expense is €0.29 Mil. CytoMed Therapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For CytoMed Therapeutics (FRA:F98), the current Other Operating Expense is €0.29 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
19GF Score
Get the complete analysis for FRA:F98
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F98 has been successfully added to your 
